Table 2. Baseline characteristics, ARV status, and infant follow-up by year of enrollment.
| Variable | Median (IQR) or percentage by year of enrollment | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013A | 2014A | Total | |
| Number of patients per enrollment year | 26 | 141 | 1048 | 2297 | 3686 | 4025 | 4295 | 4926 | 5255 | 4224 | 1581B | 31,504 |
| Maternal age at 1st visit (years) | 31 (30-33) | 29 (27-32) | 29 (26-32) | 30 (26-33) | 29 (26-33) | 30 (26-33) | 30 (27-34) | 30 (27-34) | 31 (28-34) | 31 (28-35) | 32 (28-35) | 30 (27-34) |
| Gestational age at 1st visit (weeks) | 18 (12-27) | 25 (17-31) | 26 (18-33) | 25 (17-31) | 24 (17-30) | 24 (16-30) | 23 (17-29) | 22 (16-28) | 22 (17-28) | 22 (16-28) | 22 (17-28) | 23 (17-29) |
| CD4 count at baseline (cells/mm3) | 140 (120-402) | 282 (179-386) | 310 (193-459) | 316 (207-479) | 335 (219-493) | 345 (228-503) | 349 (231-490) | 356 (234-512) | 387 (251-546) | 391 (254-549) | 415 (272-573) | 362 (234-518) |
| Viral load at baseline (copies/mL) | 9946 (200-31438) | 18538 (820-89635) | 5198 (315-39269) | 2792 (200-26317) | 2673 (200-23231) | 1932 (200-22319) | 918 (200-17802) | 417 (200-17131) | 200 (200-13225) | 200 (200-13719) | 200 (200-6953) | 846 (200-19552) |
| ARV Status, (%) | ||||||||||||
| NNRTI-based ART/prophylaxis | 50% | 71% | 50% | 47% | 44% | 49% | 64% | 84% | 87% | 90% | 92% | 70% |
| PI-based ART | - | 1% | 3% | 3% | 4% | 5% | 6% | 9% | 10% | 8% | 7% | 7% |
| Triple-NRTI ART | - | - | 0.6% | 0.7% | 0.4% | 0.3% | 0.2% | 0.4% | 0.3% | 0.05% | - | 0.3% |
| Mono/dual-NRTI prophylaxis | - | - | 14% | 22% | 23% | 24% | 20% | 2% | 0.3% | 0.2% | - | 11% |
| Single-dose NVP only | - | - | 0.7% | 0.5% | 0.4% | 0.6% | 0.2% | - | 0.02% | - | - | 0.2% |
| No ARVs received or none documented | 50% | 28% | 31% | 27% | 28% | 22% | 10% | 4% | 2% | 2% | 1% | 12% |
| No. (%) of infants with ≥1 follow-up visit | - | 5 (4%) | 430 (41%) | 1551 (68%) | 2360 (64%) | 2716 (67%) | 3005 (70%) | 3627 (74%) | 3843 (73%) | 2692 (64%) | 554 (35%) | 20783 (66%) |
| Median duration of infant follow-up (months) | - | 21 (12-21) | 17 (8-18) | 13 (6-18) | 13 (5-18) | 15 (6-18) | 17 (7-18) | 16 (9-18) | 12 (6-18) | 6 (3-10) | 2 (1-3) | 12 (5-18) |
| % of infants with ≥1 follow-up who have DNA PCR result | - | 20% | 28% | 58% | 69% | 81% | 87% | 89% | 87% | 63% | 21% | 76% |
A
Reported infant follow-up data is incomplete as there is insufficient time from maternal enrollment to delivery and 18 months follow-up for all infants (data was only analyzed through June 2014).
B
Maternal enrollment data is incomplete for 2014 as this cohort only included women enrolled through June 2014.